Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine + R-CHOP in DLBCL
NCT01004991Phase 2
Key facts
- Status
- Completed
- Start
- Jan 2010
- Primary completion
- Sep 2013
- Countries
- 1
- Sponsor
- Weill Cornell Medicine
- Modality
- Small Molecules
- Drugs
- azacitidine
- Conditions
- diffuse large B-cell lymphoma (DLBCL)
01
Overview
Phase 2, open-label, single-arm trial of azacitidine in diffuse large B-cell lymphoma (DLBCL), sponsored by Weill Cornell Medicine. Primary endpoint: Complete Response at 13 months. Started Jan 2010; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
All patients
Azacitidine + R-CHOP
03
Who it enrols
Patients with histologically confirmed CD20+ DLBCL, Stage II-IV (Stage II only if not appropriate for abbreviated therapy), no prior treatment, and adequate organ function. Excludes CNS involvement, HIV, and active Hepatitis B.
04
Endpoints
Primary
Complete Response
Beyond the preview
Go deeper on NCT01004991.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01004991.